Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Long-Term Investments (2016 - 2023)

ImmunityBio (IBRX) has disclosed Long-Term Investments for 10 consecutive years, with $891000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Long-Term Investments rose 6.07% to $891000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $891000.0, a 6.07% increase, with the full-year FY2023 number at $891000.0, up 6.07% from a year prior.
  • Long-Term Investments was $891000.0 for Q4 2023 at ImmunityBio, up from $817000.0 in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $9.3 million in Q3 2019 to a low of $769000.0 in Q3 2020.
  • A 5-year average of $2.0 million and a median of $878000.0 in 2022 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: soared 113.86% in 2019, then crashed 91.69% in 2020.
  • ImmunityBio's Long-Term Investments stood at $1.5 million in 2019, then plummeted by 36.54% to $950000.0 in 2020, then dropped by 13.47% to $822000.0 in 2021, then increased by 2.19% to $840000.0 in 2022, then increased by 6.07% to $891000.0 in 2023.
  • Per Business Quant, the three most recent readings for IBRX's Long-Term Investments are $891000.0 (Q4 2023), $817000.0 (Q3 2023), and $841000.0 (Q2 2023).